|
Cleanascite™ Cited in Ovarian Cancer Study to Overcome Immunotherapy Resistance Biotech Support Group (BSG), a leader in proteomics sample preparation, highlights a recent study utilizing its proprietary lipid removal reagent, Cleanascite™, to investigate mechanisms of immunotherapy resistance in ovarian cancer omental metastases. Press Release
Cleanascite™ Cited in Ovarian Cancer Study to Overcome Immunotherapy Resistance
MONMOUTH JUNCTION, NJ, March 18, 2026 — Biotech Support Group (BSG), a leader in proteomics sample preparation, highlights a recent study utilizing its proprietary lipid removal reagent, Cleanascite™, to investigate mechanisms of immunotherapy resistance in ovarian cancer omental metastases.
The study, led by researchers at the German Cancer Research Center (DKFZ) and published in Signal Transduction and Targeted Therapy , is titled “ Harnessing lipid-driven immunometabolic pathways in omental metastases to enhance immunotherapy in patients with ovarian cancer. ” The research explores how lipid-rich tumor environments suppress the immune system and how "skimming" these lipids can restore anti-tumor activity.
Lipid Removal Reprograms Tumor-Associated Macrophages (TAMs) The investigation found that lipid accumulation in scavenger macrophages leads to a deregulation of lipid metabolism, effectively "turning off" the immune response. By reducing lipid content—either pharmacologically or via lipid depletion of the growth medium—researchers were able to reprogram macrophages into cytotoxic cells and restore T-cell activity.
A key finding involved the use of Cleanascite™ for "skimming" ascites supernatants. The article states: “Similar to maraviroc and anti-CD36 treatment, depleting lipids from ascites associated macrophages (AAMs) by ‘skimming’ the ascites supernatants with Cleanascite™ led to a striking increase in cytokine production (Fig.), indicative of AAM activation.”
Advancing Cancer Research using Cleanascite™ The study provides a targetable metabolic-inflammatory signaling axis that could be exploited to enhance the efficacy of immunotherapy in Epithelial Ovarian Carcinoma (EOC).
“Over the last few years, numerous publications have cited Cleanascite™ to index the degree of lipid influence on tumor-associated macrophages within the tumor microenvironment,” stated Dr. Swapan Roy, President and Founder of Biotech Support Group. “It is rewarding to see our lipid removal technology contributing to critical cancer research and potential therapeutic breakthroughs.”
For
additional product details, visit:
About
Biotech Support Group LLC
For
Business Development Inquiries:
Keywords: Cleanascite™, lipid depletion, lipid removal, ovarian cancer, Tumor Associated Macrophages (TAMs), Maraviroc |
- About
- Products
- Albumin Removal Products
- Hemoglobin Removal Kits
- Lipid Removal & Clarification
- Urine Protein & Low Abundance Enrichment
- Class Specific Enrichment
- Sample Prep Mass Spectrometry
- Functional & Chemical Proteomics
- Genomic Sample Prep
- Accessories
- Technical Resources
- References
- Publications & Reports
- FAQs
- Case Studies
- Cleanascite™ Unlocks Insights into Lipid-Driven Tumor Immunosuppression
- NRicher™ Bead Platform Provides Unique Sub-Proteome Biases And Fit For Purpose Opportunities for Targeted LC-MS Quantification
- BSG Products To Assist in Analyzing Macrophage Polarization
- Ectodomain Shedding and Enrichment of the Soluble Membrane Proteome
- Investigate out of the Venn Diagram box
- Methods to selectively deplete or purify Hemoglobin from Dried Blood Spots (DBS)
- The Utility of HemoVoid™ is Demonstrated in 3 Proteomic Investigations Identifying Potential Disease Specific Biomarkers
- The 4 common features of our sample prep products, known as the BSG Advantage, are highlighted in a selection of journal references.
- AlbuVoid™ Workflows Advance Cell Secretome Proteomics
- Lipid Removal for Phenotypic Cell Response in Cancer Research
- The Influence of Sample Prep Bias on LC-MS Targeted Peptide Quantification in Serum Proteomics
- Re-imagining proteomics for developing precision medicine biomarkers of the innate immune response in SARS-CoV-2
- Patent Application Describes New Proteomic Methods to Monitor Protease Inhibitor Function During Covid-19 Infections
- Efficient Hemoglobin Removal Advances Red Cell Proteomics Offering Many New Insights Into Inflammation and Infectious Disease
- The Potential for New Blood Biomarkers in the Management of COVID-19 Disease
- Establishing the Utility of HemoVoid™ and HemogloBind™ as Enrichment Tools for Proteomic Analysis of Red Cells and Whole Blood in Parkinson’s Disease
- Species Diversity Supported By BSG Products
- Poster Report Describes Loss of Functional Serpin Activity In Cancer Patient Blood
- AlbuVoid™️ PLUS & AlbuSorb™️ PLUS Evaluating Different Windows of Observation Solves The Many Challenges of Serum Proteomics
- Tackling the Challenges of Serum Proteomics
- Lipid Removal Sample Prep for Cell Response Applications
- Sample Prep for Proteomic Analysis of Saliva
- Biotech Support Group Featured in Book, "Functional Proteomics – Methods and Protocols"
- Sample Prep Liquid Biopsy Products Suitable for Proteomic Profiling of a Variety of Body Fluid Sample Types
- Albumin and High Abundance Depletion
- Using HemogloBind™ as a Hemoglobin Binding Reagent
- Diverse technologies available for researchers to selectively bind or enrich exosomes and extracellular vesicles.
- Stroma Liquid Biopsy™ Biomarkers Profile Pan-Cancer Dysregulation of the Serum Proteome
- Diverse Depletion and Enrichment Technologies Enhance Simplicity and Efficiency of Obtaining Quality Proteomic Information
- Use On-Bead Digestion to Improve Time Required for Serum Digestion
- Using AlbuVoid™ as a Serum Protein Enrichment Kit in Functional Proteomics
- Using Cleanascite™ as a Lipid Absorption and Clarification Reagent
- Using HemoVoid to Remove Hemoglobin Before Analysis
- Blog
- Contact
- Liquid Biopsy
